<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036255</url>
  </required_header>
  <id_info>
    <org_study_id>TL-001</org_study_id>
    <nct_id>NCT02036255</nct_id>
  </id_info>
  <brief_title>Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase</brief_title>
  <official_title>Prevention of Tunneled Cuffed Catheter Malfunction With Prophylactic Use of a Taurolidine Locking Solution Containing Urokinase : a Multicentric Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of our study is to investigate whether the substitution of the standard locking
      solution with a locking solution containing taurolidine and urokinase weekly (Taurolock â„¢ U
      25,000 - www.taurolock.com ) reduces the rate of catheter dysfunction in hemodialysis
      patients with a history of TCC dysfunction requiring urokinase therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Requirement of Urokinase</measure>
    <time_frame>6 months</time_frame>
    <description>Requirement of Urokinase for thrombotic malfunction of dialyse catheter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Removal of dialysis catheter</measure>
    <time_frame>6 months</time_frame>
    <description>Removal of dialysis catheter for thrombosis and for bacteremia</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of the monthly cost of both procedures</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Patency</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Taurolidine Urokinase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taurolock Urokinase is used weekly in this arm substituting the classic Taurolock HEP500</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taurolidine Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taurolock HEP 500 is used as locking solution after each dialysis session</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taurolidine Urokinase</intervention_name>
    <arm_group_label>Taurolidine Urokinase</arm_group_label>
    <other_name>Taurolock Urokinase 25,000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taurolidine Heparin</intervention_name>
    <arm_group_label>Taurolidine Urokinase</arm_group_label>
    <arm_group_label>Taurolidine Heparin</arm_group_label>
    <other_name>Taurolock HEP 500</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult, prevalent hemodialysis patients

          -  Informed and consented

          -  Hemodialysis 3x/week via a tunneled cuffed catheter

          -  Urokinase administration at least two times during the previous 6 months (with more
             than a week between 2 administrations)

          -  Adequate catheter function during the week before inclusion (defined by blood flow
             more than 250ml/min on each dialysis session and blood flow within 15% of the maximal
             blood flow after the last Urokinase administration)

        Exclusion Criteria:

          -  Presence of heparin-induced thrombocytopenia

          -  Major hemorrhage or intracranial bleeding in the previous 3 months

          -  Pericarditis

          -  Intolerance to Taurolidine, citrate or to Urokinase

          -  Active catheter-related infection

          -  Catheter in the femoral vein
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence FB Bonkain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bracops Hospital</name>
      <address>
        <city>Anderlecht</city>
        <state>Brussels</state>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ixelles Hospital</name>
      <address>
        <city>Ixelles</city>
        <state>Brussels</state>
        <zip>1050</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brugman Hospital</name>
      <address>
        <city>Jette</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charleroi</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHWAPI</name>
      <address>
        <city>Tournai</city>
        <state>Hainaut</state>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ixelles Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1050</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghent Hospital</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Hemmelgarn BR, Moist LM, Lok CE, Tonelli M, Manns BJ, Holden RM, LeBlanc M, Faris P, Barre P, Zhang J, Scott-Douglas N; Prevention of Dialysis Catheter Lumen Occlusion with rt-PA versus Heparin Study Group. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med. 2011 Jan 27;364(4):303-12. doi: 10.1056/NEJMoa1011376.</citation>
    <PMID>21268722</PMID>
  </reference>
  <reference>
    <citation>Trerotola SO, Johnson MS, Harris VJ, Shah H, Ambrosius WT, McKusky MA, Kraus MA. Outcome of tunneled hemodialysis catheters placed via the right internal jugular vein by interventional radiologists. Radiology. 1997 May;203(2):489-95.</citation>
    <PMID>9114110</PMID>
  </reference>
  <reference>
    <citation>Di Iorio BR, Bellizzi V, Cillo N, Cirillo M, Avella F, Andreucci VE, De Santo NG. Vascular access for hemodialysis: the impact on morbidity and mortality. J Nephrol. 2004 Jan-Feb;17(1):19-25.</citation>
    <PMID>15151255</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Bonkain Florence</investigator_full_name>
    <investigator_title>Bonkain Florence, MD, UZ Brussel</investigator_title>
  </responsible_party>
  <keyword>Prevention, Thrombosis, Hemodialysis, Vascular access device</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Taurolidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

